KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CRISPR Therapeutics AG (CRSP) Other Accumulated Expenses (2016 - 2025)

CRISPR Therapeutics AG's Other Accumulated Expenses history spans 11 years, with the latest figure at $13.1 million for Q4 2025.

  • For Q4 2025, Other Accumulated Expenses rose 1978.13% year-over-year to $13.1 million; the TTM value through Dec 2025 reached $13.1 million, up 1978.13%, while the annual FY2025 figure was $13.1 million, 1978.13% up from the prior year.
  • Other Accumulated Expenses for Q4 2025 was $13.1 million at CRISPR Therapeutics AG, up from $604000.0 in the prior quarter.
  • Across five years, Other Accumulated Expenses topped out at $13.1 million in Q4 2025 and bottomed at $20000.0 in Q1 2023.
  • The 5-year median for Other Accumulated Expenses is $1.2 million (2023), against an average of $2.3 million.
  • The largest annual shift saw Other Accumulated Expenses crashed 99.12% in 2023 before it surged 24020.0% in 2024.
  • A 5-year view of Other Accumulated Expenses shows it stood at $1.3 million in 2021, then dropped by 7.98% to $1.2 million in 2022, then surged by 341.67% to $5.1 million in 2023, then tumbled by 87.73% to $631000.0 in 2024, then surged by 1978.13% to $13.1 million in 2025.
  • Per Business Quant, the three most recent readings for CRSP's Other Accumulated Expenses are $13.1 million (Q4 2025), $604000.0 (Q2 2025), and $631000.0 (Q4 2024).